Third-Degree AV Block

Third-degree (complete) AV block is defined as the complete absence of AV conduction, with no atrial impulses reaching the ventricles. The heart depends entirely on a junctional or ventricular escape rhythm for cardiac output. This is a potentially life-threatening conduction disturbance that almost always requires permanent pacemaker implantation unless attributable to a clearly reversible cause.[1-2]

• Syncope/presyncope: Most common presenting symptom; ask about sudden loss of consciousness, prodromal lightheadedness, or near-falls
• Exertional dyspnea, fatigue, exercise intolerance: Due to inability to augment heart rate
• Heart failure symptoms: Orthopnea, PND, lower extremity edema
• Chest pain: May indicate ischemic etiology (inferior or anterior MI)
• Palpitations: Awareness of slow or irregular heartbeat
• Timing: Acute onset (ischemia, drug toxicity) vs. insidious (degenerative, infiltrative)
• Medication history: Recent initiation or dose changes of AV nodal blocking agents
• Tick exposure, rash, travel: Lyme carditis in endemic areas[2]
• Recent cardiac surgery, catheter ablation, or TAVR[1]

• Hemodynamic instability: Hypotension, altered mental status, signs of shock
• Ventricular escape rate <40 bpm or wide QRS escape rhythm (infra-Hisian origin — unreliable, may fail abruptly)[1-2]
• Asystolic pauses ≥3 seconds while awake[3-4]
• Associated acute MI (especially anterior — less likely to resolve)[1][5]
• Syncope or seizure-like activity (Stokes-Adams attacks)
• New heart failure or pulmonary edema
• Ventricular arrhythmias (pause-dependent VT/torsades)

Causative/contributing agents

• Beta-blockers, verapamil, diltiazem, digoxin
• Class I and III antiarrhythmics (flecainide, amiodarone, sotalol)
• Nutraceuticals (e.g., lily of the valley)

Acute treatment agents

• Atropine 0.5–1.0 mg IV (effective for AV nodal block; may worsen infranodal block — use judiciously with wide QRS)
• Epinephrine infusion (2–10 mcg/min) or push-dose (10–20 mcg boluses)
• Dopamine infusion (5–20 mcg/kg/min)
• Isoproterenol (enhances both nodal and His-Purkinje conduction)
• Aminophylline IV — may be considered in acute inferior MI[1]
• Glucagon — for beta-blocker toxicity
• Cautions: Atropine is unlikely to improve infranodal block and may paradoxically worsen conduction in patients with wide QRS complexes suggesting His-Purkinje disease.[1]

• No specific dietary triggers for complete heart block
• Ensure adequate hydration, especially in patients with low cardiac output
• Monitor potassium and magnesium — hyperkalemia can exacerbate conduction block[8]
• Digoxin toxicity risk increases with hypokalemia, hypomagnesemia, and hypercalcemia

• Cardiovascular: Syncope, presyncope, dyspnea, chest pain, palpitations, exercise intolerance
• Neurologic: Dizziness, confusion, seizure-like episodes (Stokes-Adams)
• Pulmonary: Dyspnea on exertion, orthopnea (heart failure)
• Musculoskeletal: Muscle weakness (neuromuscular diseases — myotonic dystrophy, Kearns-Sayre)[1][9]
• Dermatologic: Erythema migrans (Lyme), malar rash (SLE)
• Constitutional: Fatigue, weight loss (sarcoidosis, malignancy)
• Rheumatologic: Joint pain, dry eyes/mouth (autoimmune etiologies)

• Family history: Sudden cardiac death, congenital heart block, cardiomyopathy, neuromuscular disease
• Maternal history: SLE or anti-Ro/La antibodies (congenital complete heart block)[1][9]
• Genetic conditions: SCN5A mutations, lamin A/C mutations, TRPM4[9]
• Social context: Outdoor activities in tick-endemic areas (Lyme), travel to Central/South America (Chagas)
• Collateral from witnesses: Observed syncope, seizure-like activity, duration of unresponsiveness

• A population-based study identified the following independent risk factors for AV block:[10]
• Advanced age (degenerative fibrosis — Lev's/Lenegre's disease)
• Chronic hypertension and elevated systolic blood pressure
• Diabetes mellitus / elevated fasting glucose
• Pre-existing bundle branch block (RBBB or LBBB — strongest ECG predictors)
• Coronary artery disease / prior MI
• Structural heart disease (valvular, cardiomyopathy)
• AV nodal blocking medications
• Infiltrative diseases: Sarcoidosis (AV block in 23–30%), amyloidosis[9]
• Post-cardiac surgery (especially valve surgery) or TAVR[1]
• Neuromuscular diseases: Myotonic dystrophy, Kearns-Sayre syndrome[1]
• The following figure illustrates multivariable-adjusted hazard ratios for risk factors associated with AV block:

• Isorhythmic AV dissociation: Atrial and ventricular rates are similar but independent — not true block (no treatment needed)[1-2]
• High-grade (advanced) second-degree AV block: ≥2 consecutive non-conducted P waves but some conduction preserved[1]
• Sinus bradycardia with junctional escape: Sinus rate slower than junctional rate — not AV block
• Drug-induced AV block: Beta-blockers, CCBs, digoxin, antiarrhythmics — may be reversible[2][6]
• Hyperkalemia: Can mimic or cause complete heart block
• Acute MI: Inferior MI (AV nodal block, often transient) vs. anterior MI (infranodal, worse prognosis)[1]
• Lyme carditis: Reversible with antibiotics; median resolution 6 days[1-2]
• Cardiac sarcoidosis: May present with AV block as initial manifestation[9]

• Prior conduction abnormalities (first-degree AV block, bundle branch block)
• History of MI, coronary artery disease, heart failure
• Prior cardiac surgery or catheter ablation
• Autoimmune/rheumatologic disease (SLE, sarcoidosis, RA)
• Neuromuscular disease
• Thyroid disease (both hypo- and hyperthyroidism)[8]
• Prior Lyme disease or tick-borne illness
• Medication list — especially AV nodal blocking agents

• Vital signs: Bradycardia (typically 25–50 bpm), hypotension, may have normal or low BP
• Irregular cannon A waves in JVP (atrial contraction against closed tricuspid valve)[11]
• Varying intensity of S1 (hallmark — due to changing PR relationship)[11]
• Varying pulse volume[11]
• Signs of heart failure: Elevated JVP, pulmonary crackles, peripheral edema
• Skin: Erythema migrans (Lyme), malar rash (SLE), erythema nodosum (sarcoidosis)
• Neurologic: Muscle wasting, myotonia (neuromuscular disease)
• Focused exam: Assess perfusion (capillary refill, mental status, urine output)

• Troponin: Rule out acute MI as cause
• BMP/CMP: Potassium (hyperkalemia), calcium, magnesium, renal function
• TSH: Hypothyroidism or hyperthyroidism[8]
• Digoxin level: If on digoxin therapy
• Lyme serologies: In endemic areas or with suggestive history[2]
• ESR/CRP, ANA, anti-Ro/La: If autoimmune etiology suspected
• ACE level, lysozyme: If sarcoidosis suspected (low sensitivity)
• BNP/NT-proBNP: Assess for heart failure
• CBC: Infection workup

• Transthoracic echocardiography (TTE): First-line — assess LV function, wall motion abnormalities, valvular disease, infiltrative cardiomyopathy[11]
• Chest X-ray: Cardiomegaly, pulmonary congestion, hilar lymphadenopathy (sarcoidosis)
• Cardiac MRI: Gold standard for sarcoidosis (late gadolinium enhancement), myocarditis, infiltrative disease
• Coronary angiography: If ischemic etiology suspected[11]
• PET scan: Cardiac sarcoidosis evaluation
• Imaging is unnecessary when the etiology is clearly degenerative in an elderly patient with known conduction disease

• Electrophysiology study (EPS): Determines site of block (supra-Hisian, intra-Hisian, infra-Hisian) when not apparent from ECG; HV interval ≥70 ms suggests infranodal disease[2][5]
• Exercise stress testing: AV block worsening with exercise suggests infranodal disease (poor prognosis); supra-Hisian block typically improves with exercise[12]
• Ambulatory ECG monitoring (Holter/event monitor): For paroxysmal complete heart block
• Carotid sinus massage: If carotid sinus hypersensitivity suspected (with caution)

Diagnostic criteria

• AV dissociation: P waves and QRS complexes march independently at different rates
• Atrial rate > ventricular rate (P-P interval < R-R interval)
• Regular R-R intervals (escape rhythm is regular)
• No consistent PR interval (varying PR relationship)

Key features to assess

• Narrow QRS escape (≤120 ms): Suggests junctional (AV nodal) origin — more stable, rate ~40–60 bpm, may respond to atropine
• Wide QRS escape (>120 ms): Suggests ventricular (infranodal) origin — less reliable, rate ~20–40 bpm, higher risk of asystole[1-2]
• QTc prolongation: Risk for torsades de pointes
• ST changes: Concurrent ischemia
• In atrial fibrillation: Complete heart block is suggested by a slow (<50 bpm) and regular ventricular response[1-2]
• The following figure illustrates the ECG patterns of different degrees of AV block, including third-degree block with AV dissociation (Panel D):

View full figure Figure 20. (A) First‐degree AV block. The PR interval is always prolonged (>200 ms); (B) second‐degree AV block 4 × 3 (Wenckebach type). The criterion AB > BC also applies in this case (see text and Figure B); (C) second‐degree AV block (Mobitz type) (BC = 2AB); (D) third‐degree AV block. A clear AV dissociation may be seen. After two QRS complexes have been conducted, there is a pause, followed by QRS (at slow frequencies) dissociated from P waves. In this case, the QRS complexes are junctional; (E) atypical Wenckebach blocks. Top: With abnormal lengthening of the increase preceding the pause (PR = x + 100) due to a concealed retrograde conduction of the preceding complex in the AV junction. Bottom: The abnormal PR shortening is due to the existence of a reciprocal complex in the AV junction; (F) example of an alternating Wenckebach block (see text). Mechanisms, Classification, and Clinical Aspects of Arrhythmias. Clinical Electrocardiography. December 31, 2020.

Severity stratification depends on

• Hemodynamic stability: Stable vs. unstable (hypotension, altered mental status, shock)
• Escape rhythm characteristics: Narrow QRS (junctional) = more stable; wide QRS (ventricular) = high risk[1-2][14]
• Site of block: AV nodal block has slower progression and more reliable escape; infranodal block may progress rapidly and unpredictably[2][14]
• Etiology: Reversible (Lyme, drug toxicity, inferior MI) vs. irreversible (degenerative, post-surgical)
• Complications: Heart failure, ventricular arrhythmias, cardiogenic shock
• Third-degree AV block in the setting of anterior MI carries a worse prognosis than inferior MI, as it indicates extensive septal necrosis and infranodal block.[1][5]

Initial stabilization

• ABCs, IV access, continuous telemetry, transcutaneous pacing pads applied immediately
• Atropine 0.5–1.0 mg IV q3–5 min (max 3 mg) — for suspected AV nodal block (narrow QRS). Avoid or use cautiously with wide QRS escape
• If atropine fails: Transcutaneous pacing as bridge, or epinephrine/dopamine infusion
• Temporary transvenous pacing for refractory symptomatic bradycardia[7-8][15]

Definitive treatment

• Permanent pacemaker implantation is recommended (Class I) for acquired third-degree AV block not attributable to reversible or physiologic causes, regardless of symptoms[1-2]
• In patients with reversible causes (Lyme carditis, drug toxicity), treat the underlying cause first with temporary pacing support as needed; permanent pacing if block does not resolve[2][8]
• For cardiac sarcoidosis: Permanent pacing with consideration of ICD capability[2][8]
• For acute MI: Temporary pacing; permanent pacing only if block persists after revascularization[1]
• The 2018 ACC/AHA/HRS guideline algorithm for management of chronic AV block is shown below:

View full figure Figure 7. Management of Bradycardia or Pauses Attributable to Chronic Atrioventricular Block Algorithm 2018 ACC/AHA/HRS Guideline on The Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. August 19, 2019.

• All patients with third-degree AV block require admission with continuous telemetry monitoring[14]
• ICU/CCU admission: Hemodynamically unstable, requiring temporary pacing, or associated with acute MI
• Telemetry floor: Hemodynamically stable with reliable junctional escape, awaiting permanent pacemaker
• Cardiology/EP consultation: Required for all patients — for permanent pacemaker planning
• Discharge: Only after permanent pacemaker implantation or after confirmed resolution of a reversible cause with appropriate follow-up
• Distal (infranodal) block requires arrhythmia monitoring until pacemaker implantation, as it can progress rapidly and unpredictably and has been associated with sudden death[14]

Post-pacemaker implantation

• Device check at 2–12 weeks, then every 6–12 months (or per remote monitoring schedule)
• Wound check at 1–2 weeks
• Activity restrictions for 4–6 weeks (avoid raising ipsilateral arm above shoulder)
• Return precautions (pre-pacemaker or if discharged with reversible cause):
• Return immediately for syncope, presyncope, severe dizziness, chest pain, or dyspnea
• New or worsening heart failure symptoms
• Palpitations or awareness of very slow heart rate

Expected course

• Lyme carditis: AV block typically resolves within 1–2 weeks of antibiotics (median 6 days, range up to 42 days)[1-2]
• Inferior MI: AV block often resolves within days to weeks[1]
• Degenerative/irreversible causes: Permanent pacemaker provides definitive treatment with excellent long-term outcomes[2]

1. 2018 ACC/­AHA/­HRS Guideline on The Evaluation and Management Of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/­American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.

2. 2018 ACC/­AHA/­HRS Guideline on The evaluation and Management Of patients With Bradycardia and Cardiac conduction Delay: A Report of the American College of Cardiology/­American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Writing Committee Members, Kusumoto FM, Schoenfeld MH, et al. Heart Rhythm. 2019.

3. 2012 ACCF/­AHA/­HRS Focused Update Incorporated Into the ACCF/­AHA/­HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/­American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. — Epstein AE, DiMarco JP, Ellenbogen KA, et al. Journal of the American College of Cardiology. 2013.

4. ACC/­AHA/­HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/­American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/­AHA/­NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) Developed in Collaboration With the American Association for Thoracic Surgery and Society of Thoracic Surgeons. — Epstein AE, DiMarco JP, Ellenbogen KA, et al. Journal of the American College of Cardiology. 2008.

5. Pacemakers. — Aldaas OM, Roberge-Lacharite AS, Birgersdotter-Green U. NEJM Evidence. 2025.

6. Clinical Significance and Management of Atrioventricular Block Associated With Bradycardic/­Antiarrhythmic Drug Therapy: Drug‐Induced or Drug‐Revealed?. — Sfairopoulos D, Bazoukis G, Sideris S, et al. Journal of Cardiovascular Electrophysiology. 2025.

7. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Wigginton JG, Agarwal S, Bartos JA, et al. Circulation. 2025.

8. 2018 ACC/­AHA/­HRS Guideline on The evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/­American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. — Writing Committee Members, Kusumoto FM, Schoenfeld MH, et al. Heart Rhythm. 2019.

9. Etiology and device therapy in complete atrioventricular block in pediatric and young adult population: Contemporary review and new perspectives. — Cioffi GM, Gasperetti A, Tersalvi G, et al. Journal of Cardiovascular Electrophysiology. 2021.

10. Risk Factors Associated With Atrioventricular Block. — Kerola T, Eranti A, Aro AL, et al. JAMA Network Open. 2019.

11. An Unusual Cause of Atrioventricular Block. — Rajendran K, Alphonse AJ, Desabandhu V. JAMA Internal Medicine. 2025.

12. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. — Writing Committee Members, Shah MJ, Silka MJ, et al. Heart Rhythm. 2021.

13. Mechanisms, Classification, and Clinical Aspects of Arrhythmias. — Antoni Bayés De Luna, Miquel Fiol‐Sala, Antoni Bayés‐Genís, et al. Clinical Electrocardiography. 2021.

14. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.

15. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Panchal AR, Bartos JA, Cabañas JG, et al. Circulation. 2020.

16. 2018 ACC/­AHA/­HRS Guideline on The Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/­American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.